Morphotek will apply its Libradoma technology to isolate and initially characterize candidate antibodies and the National Institute of Allergy and Infectious Diseases (NIAID) will further characterize the antibodies to identify candidates potentially useful in treating and preventing certain infectious diseases.
Morphotek’s Libradoma technology is said to generate libraries of hybridomas that can be rapidly screened to identify monoclonal antibodies against disease-associated antigens.
Nicholas Nicolaides, president and CEO of Morphotek, said: “We remain committed to advancing candidates for clinical development in this therapeutic area, which if promising, may one day become available to patients with infectious disease.”